ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2741

Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort

Richard Holland1, William Tillett1,2, Eleanor Korendowych1, Charlotte Cavill1,3, Mel Brooke4 and Neil J McHugh5, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 3Rheumatology, Bath Institute for Rheumatic Disease, Bath, United Kingdom, 4PsAZZ Support Group, Bath, United Kingdom, 5Royal National Hospital for Rheumatic Diseases and Dept Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Outcome measures, patient outcomes and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient reported outcomes (PROs) have been found to be reliable indicators of baseline status, change during treatment, and are predictive of long-term outcome. A EULAR taskforce developed the PsAID questionnaire as an impact measure of psoriatic arthritis (PsA) for use in clinical trials (PsAID9) and routine practice (PsAID12). We set out to validate the PsAID in an independent prospective cohort.  

Methods: Data were collected prospectively for a single-centre cohort of PsA patients between July 2015 and January 2016.  Clinical measures and PROs including the PsAID were completed at baseline and the PsAID was repeated at 1 week.  The primary objective was to assess the reliability of the PsAID in stable patients with PsA.  Construct validity was assessed through correlation of the PsAID with other PROs including HAQ-DI, EuroQol (EQ-5D), Psoriatic Arthritis Quality of Life questionnaire (PsAQoL), Dermatology Life Quality Index (DLQI), visual analogue scale (VAS) scores for patient global assessment (PtGA), and joint global assessment (JtGA), as well as clinical measures.  The influence of sex and disease activity as measured by the modified Composite Psoriatic Disease Activity Index (mCPDAI) was also assessed.

Results: Seventy-six patients (37 males) were recruited to the study.  The median age was 56 years (IQR 14.25); 57 patients were treated with biologics, and 13 with conventional DMARDs.  The median tender joint count was 2 (IQR 7), median swollen joint count was 0 (IQR 2) and median mCPDAI was 2 (IQR 2).  Mean (SD) baseline PsAID12 score was 3.11 (2.29) and at 1 week was 3.06 (2.33).  Intraclass correlation coefficient (ICC) was 0.93 (95% CI 0.88-0.96).  Mean baseline PsAID9 score was 3.30 (2.38) and at 1 week was 3.22 (2.41) and ICC was 0.93 (95% CI 0.88-0.96).  There was a weak floor effect with 37% of scores ≤2 and 8% of scores >7.  The PsAID correlated strongly with most PROs (Table 1).  There was a significant difference between sexes, with a mean PsAID12 in males of 1.97 (2.12) and in females 4.03 (2.01).  When individual components of the PsAID12 were analysed females scored significantly higher in 9 of the 12 items.  The correlation between the PsAID12, other PROs and clinical measures was stronger in males than females (Table 1).  Out of the patients that fulfilled MDA criteria, only 1 patient had a PSAID12 score >4, the threshold for the patient acceptable symptom state (PASS).  

Conclusion: In this cohort, the PsAID questionnaire had excellent test-retest reliability.  There was a weak floor effect, likely related to the low disease activity of the cohort as measured by the mCPDAI.  There was strong to moderate correlation with clinical and PRO measures providing evidence for the construct validity of the PsAID in this cohort, however females scored significantly higher than males with overall weaker correlation.  Prospective data collection is underway to assess sensitivity to change.  

TABLE 1: Comparison of the PsAID with PROs and clinical measures (Spearman correlation coefficient)

PsAID12 (r)

PsAID9 (r)

PsAID12 (r) Females

PsAID12 (r) Males

PsAQoL

0.846

0.835

0.717

0.762

JtGA

0.737

0.762

0.645

0.672

EQ5D

-0.726

-0.731

-0.572

-0.711

PtGA

0.689

0.713

0.525

0.705

HAQ

0.638

0.640

0.478

0.637

mCPDAI

0.560

0.553

0.244

0.616

Tender Joint Count

0.557

0.551

0.268

0.615

Swollen Joint Count

0.476

0.486

0.212

0.466

DLQI

0.101

0.085

0.087

0.347

 


Disclosure: R. Holland, None; W. Tillett, None; E. Korendowych, UCB, 5,Abbvie, 5,Janssen Pharmaceutica Product, L.P., 5,Celgene, 5,Novartis Pharmaceutical Corporation, 5; C. Cavill, None; M. Brooke, None; N. J. McHugh, None.

To cite this abstract in AMA style:

Holland R, Tillett W, Korendowych E, Cavill C, Brooke M, McHugh NJ. Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/reliability-and-construct-validity-of-the-psoriatic-arthritis-impact-of-disease-psaid-questionnaire-independent-validation-study-in-a-uk-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-and-construct-validity-of-the-psoriatic-arthritis-impact-of-disease-psaid-questionnaire-independent-validation-study-in-a-uk-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology